Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today a reduction of approximately 15% of its workforce, which included positions in all functions of the Company's business. Following the reduction, the Company's headcount numbers 76 people.

The workforce reduction is intended to further focus Company resources on expanding the commercial use of its genomics analysis technology, Massively Parallel Signature Sequencing (MPSS™), which provides comprehensive and quantitative digital gene expression information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries.

"We appreciate the contributions made by former employees and offer them our sincere thanks," said Kevin Corcoran, president and chief executive officer. We plan to expand into new applications for DNA sequencing services, where we see ample commercial opportunity, while further developing our gene expression services business. We believe that customers are becoming increasingly aware of the advantages of our MPSS™ process, which include our technology's ability to provide bankable, quantitative information about the activity of virtually every gene in a sample. We believe we are well positioned to execute on our strategy, while keeping costs under control."

Lynx is a leader in the development and application of novel genomics analysis solutions that provide comprehensive and quantitative digital gene expression information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. These solutions are based on Megaclone™ and MPSS™, Lynx's unique and proprietary cloning and sequencing technologies.